Cargando…

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features

CONTEXT: Alemtuzumab, a highly effective treatment for multiple sclerosis (MS), predisposes to Graves disease (GD), with a reportedly indolent course. OBJECTIVE: To determine the type, frequency, and course of thyroid dysfunction (TD) in a cohort of alemtuzumab-treated patients with MS in the United...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pariani, Nadia, Willis, Mark, Muller, Ilaria, Healy, Sarah, Nasser, Taha, McGowan, Anne, Lyons, Greta, Jones, Joanne, Chatterjee, Krishna, Dayan, Colin, Robertson, Neil, Coles, Alasdair, Moran, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2018
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097600/ https://www.ncbi.nlm.nih.gov/pubmed/29878256 http://dx.doi.org/10.1210/jc.2018-00359

Ejemplares similares

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
por: Phelps, Richard, et al.
Publicado: (2019)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
por: Coles, Alasdair J., et al.
Publicado: (2021)

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
por: De Mercanti, Stefania, et al.
Publicado: (2016)

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods
por: Khoo, Serena, et al.
Publicado: (2020)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
por: Arnold, Douglas L., et al.
Publicado: (2016)

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
por: Coles, Alasdair J., et al.
Publicado: (2017)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Contrasting Phenotypes in Resistance to Thyroid Hormone Alpha Correlate with Divergent Properties of Thyroid Hormone Receptor α1 Mutant Proteins
por: Moran, Carla, et al.
Publicado: (2017)

Detecting and predicting neutralization of alemtuzumab responses in MS
por: Saxena, Gauri, et al.
Publicado: (2020)

OR26-06 Cardiovascular Morbidity And Mortality In Patients With Resistance to THYROID Hormone (RTH): A Linked Record Study
por: Okosieme, Onyebuchi, et al.
Publicado: (2023)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Hyperthyroxinemia and Hypercortisolemia due to Familial Dysalbuminemia
por: Moran, Carla, et al.
Publicado: (2020)

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
por: Brannigan, Jamie, et al.
Publicado: (2020)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
por: Wiendl, Heinz, et al.
Publicado: (2019)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
por: Havrdova, Eva, et al.
Publicado: (2017)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Alemtuzumab induction in pediatric kidney transplantation
por: Kaabak, Michael M, et al.
Publicado: (2013)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

ALEMTUZUMAB FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION
por: Girgis, Reda, et al.
Publicado: (2020)

Alemtuzumab: Infections: 4 case reports
Publicado: (2020)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

An Unusual Etiology of Graves’ Disease: Alemtuzumab
por: Santiago Carrion, Ada Marie, et al.
Publicado: (2021)

Alemtuzumab: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Alemtuzumab-Induced Autoimmune Thyroid Dysfunction
por: Ragavan, Sharanniyan, et al.
Publicado: (2022)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Mycobacterium haemophilum Infection after Alemtuzumab Treatment
por: Kamboj, Mini, et al.
Publicado: (2008)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Alemtuzumab induction therapy in solid organ transplantation
por: Friend, Peter J
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ggtgs10f0bin82ulf1occdhfs3